FindTrial
Sign In

RMC-6291

DRUG3 trials

Sponsors

Revolution Medicines Inc., Revolution Medicines, Inc.

Conditions

Advanced Solid TumorColorectal Cancer (CRC)KRAS G12C-mutated Solid Tumors, Lung CancerKRAS, NRAS, HRAS-mutated NSCLCLung CancerLung Cancer Stage IV, Advanced Solid Tumor, CancerNon-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancer, NSCLC

Phase 1

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Active, not recruitingNCT05462717
Revolution Medicines, Inc.Advanced Solid Tumor, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC) +1
Start: 2022-09-19End: 2025-12-31Target: 222Updated: 2024-11-07
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecruitingNCT06162221
Revolution Medicines, Inc.KRAS G12C-mutated Solid Tumors, Lung Cancer, KRAS, NRAS, HRAS-mutated NSCLC, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer +2
Start: 2024-01-18End: 2028-12-01Target: 616Updated: 2026-03-09
Study of RMC-6291, With or Without RMC-6236, in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
RecruitingCTIS2023-509571-16-00
Revolution Medicines Inc.Lung Cancer
Start: 2024-07-17Target: 162Updated: 2025-12-17

Related Papers

Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors
Cancer Research2025-05-224 citations
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
Journal of Medicinal Chemistry2025-03-0832 citations
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
Journal of Medicinal Chemistry2025-02-2422 citations
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Cancer Discovery2024-04-09213 citations
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Science2023-08-17199 citations